Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i> BRAF <sup>V600E</sup> </i> -Mutated Anaplastic Thyroid CarcinomaJennifer Wang, Maria E. Cabanillas, Mark Zafereo et al.|Thyroid|2019Cited by 229
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal DiseasesAnne R. Bass, James Reston, Eliza F. Chakravarty et al.|Arthritis Care & Research|2023Cited by 203
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF <sup>V600E</sup> -Mutated Anaplastic Thyroid CarcinomaSarah Hamidi, Maria E. Cabanillas, Naifa L. Busaidy et al.|Thyroid|2024Cited by 72
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal DiseasesAnne R. Bass, James Reston, Eliza F. Chakravarty et al.|Arthritis & Rheumatology|2023Cited by 68
Toxicity in the era of immune checkpoint inhibitor therapySynat Keam, Roza Nurieva, Naimah Turner et al.|Frontiers in Immunology|2024Cited by 56